Meet Fred. He drives your pipeline forward.
Fred evaluates opportunities, identifies partners, drafts outreach, and runs diligence continuously. Your team makes every strategic decision. Fred makes sure nothing stalls between steps.
Meet Fred.
Your AI Lifecycle Manager.
The Playground gives you answers. Fred gives you execution. He evaluates opportunities, identifies partners, drafts outreach, and runs diligence continuously so your pipeline never stalls between steps.
Real deliverables, not chat responses
Scorecards, ranked shortlists, outreach drafts, diligence reports. Assets you can present and act on immediately.
Lives in your pipeline, not a separate tool
Fred posts findings to your deal channels and surfaces the next required action where your team already works.
Learns over time. Context compounds.
Every analysis builds your private knowledge graph. Fred never forgets. Each launch makes the next one faster.
Atorvastatin, Brazil: Viability Update
I've completed the re-evaluation. Market import volume grew 23% YoY. ANVISA's generic pathway has a 14-month median approval time. Three new API suppliers entered since your last review. Updated scorecard attached.
Recommended next action
Partner shortlist is ready. Top match is Aurobindo (92% fit score based on trade volume, GMP status, and Brazil regulatory footprint). Draft outreach is prepared for your review.
Give Fred a molecule and a market. He drives it forward.
Each capability removes the specific blocker that causes a lifecycle stage to stall.
Viability becomes a score, not a meeting
Market size, competition, regulatory landscape, and supply chain scored in minutes. Not a 40-slide deck that took three weeks.
Viability Assessment
Atorvastatin - Brazil
Strong market opportunity with established import demand. Moderate competition from 4 existing suppliers. Favorable regulatory pathway via ANVISA.
Partners ranked by data, not Rolodex
300M+ data points searched for companies already operating in your molecule-market. Ranked by volume, reliability, and regulatory alignment.
Partner Shortlist
Atorvastatin - Brazil · 5 matches
| # | Company | Country | Volume | Fit | Reliability |
|---|---|---|---|---|---|
| 1 | Eurofarma | Brazil | $48M | 92 | A+ |
| 2 | Cristalia | Brazil | $31M | 87 | A |
| 3 | Libbs | Brazil | $22M | 74 | B+ |
| 4 | Blau Farmaceutica | Brazil | $18M | 71 | B |
| 5 | Aché Laboratorios | Brazil | $14M | 68 | B |
Outreach writes itself
Personalized emails citing real import volumes, growth rates, and competitive positioning. Data your partners respect, not a cold template.
Dear BD Team,
We are reaching out regarding a potential API supply partnership for Atorvastatin in Brazil.
Our analysis of Brazilian import data shows that Atorvastatin API imports grew 23% YoY, reaching $142M in 2024. Eurofarma currently sources from 3 suppliers, and we believe there is an opportunity to strengthen your supply chain with a competitive, reliable partner.
Data-backed talking points:
- • Brazil imported $142M of Atorvastatin API in 2024 (+23% YoY)
- • Eurofarma holds 18% market share in cardiovascular FDFs
- • Current supplier concentration risk: top 2 suppliers cover 67% of volume
We'd welcome the opportunity to discuss how we can support your Atorvastatin program. Would you be available for a 30-minute call next week?
Generated by Fred · Based on PharmaDB trade intelligence
Diligence happens before you ask
Regulatory status, trade history, financial health, and IP risk checked for every partner on your shortlist. Red flags surface before you commit.
Due Diligence Report
Eurofarma · Brazil
Fred proposes. You decide. The pipeline never stalls.
Fred's findings surface in DealFlow. You review, decide, and move forward. Scheduled tasks run overnight. Every opportunity has an owner.
Fred works between meetings
Scheduled scans run overnight. You wake up to new evaluations, updated shortlists, and fresh competitive intelligence.
You decide what progresses
Every suggestion is a proposal. Approve a partner match. Refine an outreach draft. Your team makes the calls.
Opportunities advance automatically
Approved actions flow into the Portfolio Board. Stages progress from Ideas through Evaluating to Closed. No status meetings required.
Fred found 3 partners for Atorvastatin in Brazil
Top match: Eurofarma (fit score 92/100, $48M trade volume)
Losartan in Kenya scores 7.8/10 viability
High market demand, moderate competition. Recommended for pipeline.
Outreach draft ready for Cipla (Ciprofloxacin - Egypt)
Personalized email with trade data talking points. Ready for review.
Due diligence complete for Eurofarma (Brazil)
2 yellow flags (regulatory timeline), 0 red flags. Overall: low risk.
Scheduled Tasks
Pipeline scan - new opportunities
Scans trade data for molecules matching your criteria
Competitive monitoring - Atorvastatin
Tracks new exporters and price movements
Partner health check
Monitors trade activity of shortlisted partners
Regulatory alerts - target markets
Flags new approvals and policy changes
Pipeline summary digest
Weekly summary of all pipeline changes
Fred doesn't wait for you to ask.
Fred monitors your pipeline and the broader market continuously, surfacing what matters before you think to look for it.
Daily pipeline scans
New opportunities matching your criteria, every morning.
Competitive monitoring
New exporters, price shifts, supply chain changes.
Partner health checks
Ongoing surveillance of shortlisted partners' activity.
Cumulative memory
Every analysis builds your organization's knowledge graph.
Fred is powered by the full PharmaDB stack.
Explore the data foundation and the query layer that make Fred possible.
Common questions
What exactly is Fred?
Fred is an autonomous AI lifecycle manager built on top of the Pharma Graph. He doesn't just answer questions. He drives your pipeline forward: evaluating viability, identifying partners, drafting outreach, and running diligence continuously. He posts findings to your workspace and surfaces the next required action so opportunities never stall between steps.
Is Fred a dashboard or a chatbot?
Neither. Fred has structured skills with defined outputs: a viability scorecard, a ranked partner list, a draft email, a diligence report. He operates inside your workspace, posting findings to DealFlow, advancing opportunities through your pipeline, and running scheduled tasks in the background. There's a direct message channel for ad-hoc questions, but that's supplementary.
Does Fred replace our BD team?
No. Fred replaces the repetitive data work and follow-through that causes opportunities to stall: the market sizing, the partner screening, the template emails, the diligence checklists. Your BD team makes every strategic decision. Fred makes sure they have what they need to decide faster, and that nothing drifts between steps.
How is Fred different from the Playground?
The Playground is for exploration: query the Pharma Graph, get structured data back. Fred is for execution: give him a molecule and a market, and he drives it through your entire pipeline. The Playground gives you data. Fred gives you action, deliverables, and continuous follow-through.
What are Fred's four skills?
Evaluate Viability (market size, competition, regulatory landscape scored in minutes), Find Partners (companies already operating in your molecule-market, ranked by data), Draft Outreach (personalized emails citing real trade data), and Partner Due Diligence (regulatory status, trade history, financial health, and IP risk checked automatically).
How does the workspace work?
Fred posts findings to DealFlow, your team's pipeline feed. You review proposals, approve actions, and watch opportunities advance through Portfolio Board stages. Scheduled tasks run overnight so you wake up to fresh evaluations, updated shortlists, and competitive intelligence.
See Fred advance a real opportunity. Live.
Book a 30-minute demo. We'll run Fred on your pipeline.